A Study to Investigate the Effect of the IRAK4 inhibitor (AZD6793) in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

This is a Phase IIb, randomized, placebo controlled study evaluating the efficacy and safety of 3 different doses of AZD6793 (5, 15 and 45 mg once a day and oral tablet) in patients with moderate to severe COPD with at least 2 outpatient exacerbations or one hospitalization in the past year.

AZD6793 has a broad anti-inflammatory activity by inhibiting the pathways downstream of interleukin 1 receptor-like 1 (ST2) which is the receptor for IL-33, IL-1β, IL-18, IL-36 and various other toll-like receptors, thus reducing both neutrophilic and eosinophilic inflammation.

Primary End-Points:
  • Annualized rate of moderate/severe exacerbations
Presto SIV slides V 7.0-6
Key inclusion criteria are:
  • COPD GOLD E
  • post-BD FEV1 ≥ 25% to < 80%
  • On dual or triple inhaler therapy
ClinicalTrials.gov Identifier: NCT07082738

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!